Literature DB >> 1836957

Post- thymic in vivo expansion of mature alpha beta T cells.

P Pereira1, B Rocha.   

Abstract

To discriminate whether peripheral T cell expansion is a property of pluripotent T cell precursors or of T lymphocytes precommitted to the expression of a single T cell receptor, we have evaluated the repopulation capacity of T lymphocytes expressing defined V beta gene products after transfer into syngeneic nude mice. The results showed no difference in the expansion potential of cells expressing different V beta s. The frequency of cells bearing different V beta gene products in the donor and the expanded cell populations are very similar, even when sorted populations enriched or deleted in T cells expressing a defined V beta gene product were used as a source of donor cells. These results demonstrate that peripheral T cells expressing alpha beta TCR are fully competent of extensive division in the peripheral pools.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836957     DOI: 10.1093/intimm/3.11.1077

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  The survival and turnover of mature and immature CD8 T cells.

Authors:  M McDonagh; E B Bell
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

2.  Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts.

Authors:  A W Goldrath; M J Bevan
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

3.  The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool.

Authors:  S P Berzins; R L Boyd; J F Miller
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

4.  Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.

Authors:  W Held; A N Shakhov; S Izui; G A Waanders; L Scarpellino; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.